Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
Recruiting
Phase 1/Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| acalabrutinib | ACP-196 | Part 1: acalabrutinib Regimen 1 |
| rituximab (IV) | Part 1: acalabrutinib Regimen 2 | |
| Lenalidomide | Part 3: acalabrutinib Regimen 1 |
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects
with B-cell Non-Hodgkin Lymphoma
| Name | Type | Description | Interventions |
|---|---|---|---|
| Part 1: acalabrutinib Regimen 1 | Experimental | acalabrutinib Regimen 1 |
|
| Part 1: acalabrutinib Regimen 2 | Experimental | acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects |
|
| Part 2: acalabrutinib Regimen 1 | Experimental | acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects |
|
| Part 2: acalabrutinib Regimen 2 | Experimental | acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects |
|
| Part 3: acalabrutinib Regimen 1 | Experimental | acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects |
|
Inclusion Criteria:
- Men and women ≥ 18 years of age.
- Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or
been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously
received systemic anticancer therapy for FL., and which requires treatment.
- Part 2:Histologically confirmed MZL including splenic, nodal, and extranodal sub-
types
1. Subjects with splenic MZL must have an additional measurable lesion, nodal or
extranodal, as described in inclusion criterion #4;
2. Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be
Helicobacter pylori (HP)-negative
- Part 3: For subjects with FL: Pathologically confirmed diagnosis of FL Grade 1, 2, or
3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL and which
requires treatment per National Cancer Institute or ESMO clinical practice guidelines.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Agreement to use contraception during the study and for 30 days after the last dose of
study drugs if sexually active and able to bear or beget children.
Exclusion Criteria:
- •A life-threatening illness, medical condition or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction within 6 months of screening, or
any Class 3 or 4 cardiac disease as defined by the New York Heart Association
Functional Classification, or Qtc >480 msec
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory
bowel disease, or partial or complete bowel obstruction.
- Breast feeding or pregnant
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Number of Participants With Treatment Emergent Adverse Events (AEs) |
| Time Frame: | From first dose of study drug to within 30 days of last dose of study drug |
| Safety Issue: | |
| Description: | Number of participants who had experienced at least one treatment emergent AE |
| Phase: | Phase 1/Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Acerta Pharma BV |
June 19, 2019
